Hepatitis C Management in Special Populations

  • Author: Mark S. Sulkowski, MD (More Info)
  • Editor In Chief: Stefan Zeuzem, MD
  • Last Reviewed: 8/17/18 (What's New)

Summary

  • The impact of end-stage renal disease on liver disease progression in patients with HCV is not well defined due to high mortality in patients on long-term HD
  • Anti-HCV antibody positivity in patients on long-term HD has been associated with increased risk of death due to cardiovascular disease[Fabrizi 2012]
  • The impact of immunosuppression on HCV disease progression following renal transplantation is unclear:

    Action required

    Keywords: Hepatitis C, Hepatitis C-Pathogenesis and Natural History, Hepatitis C-Special Populations

    ©2020 Clinical Care Options, LLC. All Rights Reserved.

    The materials published via inPractice® reflect the views of the reviewers or authors of the material, not those of Clinical Care Options, LLC, the accredited provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.